What Is the Treatment of Aneurysmal Bone Cyst? First-Line Protocol
Aneurysmal bone cyst (ABC) is a benign but locally destructive lesion requiring targeted intervention. This protocol defines the first-line management approach, with the clinical goal of achieving healing and repair of the bone cyst lesion.
Clinical Goal
The objective of treatment is healing and repair of the bone cyst lesion. Evidence supports a percutaneous approach as appropriate first-line therapy, with responses documented across multi-injection treatment courses.
Treatment Approach — Partial Overview
First-line management involves a percutaneous, image-guided sclerotherapy technique. The procedure is performed under fluoroscopic guidance and requires anesthetic support.
References
DOI: 10.7759/cureus.53587
- Polidocanol sclerotherapy, on the other hand, is an appropriate first-line therapy.
- Percutaneous sclerotherapy has emerged as an excellent approach to treating ABCs in recent years.
- Polidocanol is a safe and effective sclerotherapy for ABCs, with few side effects.
- The procedure does require technical expertise with local/general anesthesia and is done under fluoroscopic guidance with added radiation exposure.
- Rastogi et al. reported a clinical response of 84.5% of 72 patients, with an average follow-up of 34 months and three injections given to each patient on average.
- Sclerosants cause damage to the vascular endothelium, promote thrombosis in small blood vessels, and trigger a series of intricate processes that culminate in the repair of the lesion.